Yin Z - Search Results

1

Down-regulation of WWP2 aggravates Type 2 diabetes mellitus-induced vascular endothelial injury through modulating ubiquitination and degradation of DDX3X.

You S, Xu J, Yin Z, Wu B, Wang P, Hao M, Cheng C, Liu M, Zhao Y, Jia P, Jiang H, Li D, Cao L, Zhang X, Zhang Y, Sun Y, Zhang N. You S, et al. Among authors: yin z. Cardiovasc Diabetol. 2023 May 6;22(1):107. doi: 10.1186/s12933-023-01818-3. Cardiovasc Diabetol. 2023. PMID: 37149668 Free PMC article.

2

Regulation of the Tec family of non-receptor tyrosine kinases in cardiovascular disease.

Yin Z, Zou Y, Wang D, Huang X, Xiong S, Cao L, Zhang Y, Sun Y, Zhang N. Yin Z, et al. Cell Death Discov. 2022 Mar 16;8(1):119. doi: 10.1038/s41420-022-00927-4. Cell Death Discov. 2022. PMID: 35296647 Free PMC article. Review.

3

The role of SMURFs in non-cancerous diseases.

Wang D, Zou Y, Huang X, Yin Z, Li M, Xu J, Wu B, Li D, Zhang Y, Sun Y, Zhang X, Zhang N. Wang D, et al. Among authors: yin z. FASEB J. 2023 Aug;37(8):e23110. doi: 10.1096/fj.202300598R. FASEB J. 2023. PMID: 37490283 Review.

4

Atorvastatin rescues vascular endothelial injury in hypertension by WWP2-mediated ubiquitination and degradation of ATP5A.

Yin Z, You S, Zhang S, Zhang L, Wu B, Huang X, Lu S, Cao L, Zhang Y, Li D, Zhang X, Liu J, Sun Y, Zhang N. Yin Z, et al. Biomed Pharmacother. 2023 Oct;166:115228. doi: 10.1016/j.biopha.2023.115228. Epub 2023 Aug 7. Biomed Pharmacother. 2023. PMID: 37557013 Free article.

5

Interleukin-21 receptor signaling promotes metabolic dysfunction-associated steatohepatitis-driven hepatocellular carcinoma by inducing immunosuppressive IgA⁺ B cells.

Xie Y, Huang Y, Li ZY, Jiang W, Shi NX, Lu Y, Cao G, Yin Z, Lin XJ. Xie Y, et al. Among authors: yin z. Mol Cancer. 2024 May 8;23(1):95. doi: 10.1186/s12943-024-02001-2. Mol Cancer. 2024. PMID: 38720319

6

Bacteroidota inhibit microglia clearance of amyloid-beta and promote plaque deposition in Alzheimer's disease mouse models.

Wasén C, Beauchamp LC, Vincentini J, Li S, LeServe DS, Gauthier C, Lopes JR, Moreira TG, Ekwudo MN, Yin Z, da Silva P, Krishnan RK, Butovsky O, Cox LM, Weiner HL. Wasén C, et al. Among authors: yin z. Nat Commun. 2024 May 8;15(1):3872. doi: 10.1038/s41467-024-47683-w. Nat Commun. 2024. PMID: 38719797

7

Omics-based pharmacological evaluation reveals Yuanhu Zhitong oral liquid ameliorates arthritis by regulating PKC/ERK/NF-κB signaling pathway.

Zhang K, Yin Z, Chen F, Cao Z, Guan J, Chen C, Wang Y, Fan G. Zhang K, et al. Among authors: yin z. J Ethnopharmacol. 2024 May 6:118289. doi: 10.1016/j.jep.2024.118289. Online ahead of print. J Ethnopharmacol. 2024. PMID: 38718892

8

Cross-species single-cell analysis uncovers the immunopathological mechanisms associated with IgA nephropathy progression.

Chen X, Wang T, Chen L, Zhao Y, Deng Y, Shen W, Li L, Yin Z, Zhang C, Cai G, Zhang M, Chen X. Chen X, et al. Among authors: yin z. JCI Insight. 2024 May 8;9(9):e173651. doi: 10.1172/jci.insight.173651. JCI Insight. 2024. PMID: 38716725

9

Tumor burden affects the progression pattern on the prognosis in patients treated with sorafenib.

Sun J, Xia D, Bai W, Li X, Wang E, Yin Z, Han G. Sun J, et al. Among authors: yin z. Front Oncol. 2024 Apr 23;14:1405178. doi: 10.3389/fonc.2024.1405178. eCollection 2024. Front Oncol. 2024. PMID: 38715786 Free PMC article.

10

The effect of lipid-lowering therapy on lipid-related residual risk factors: a prospective study.

Li Z, Gao Y, Lu Q, Yin Z, Zhang S, Zhang W, Sui Y, Xu Y, Li J, Dou K, Qian J, Qiu H, Wu N. Li Z, et al. Among authors: yin z. Lipids Health Dis. 2024 May 7;23(1):134. doi: 10.1186/s12944-024-02078-0. Lipids Health Dis. 2024. PMID: 38715079

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

7,571 results

Search Page